CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 300 target
Drug / intervention
Ivermectin w/ Albendazole +3 moredrug
Likely dose
Ivermectin w/ Albendazole 150 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06070116
NCT06070116Phase 2ActiveOn TrackUpdated 6mo ago
CompareCT.gov

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

Washington University School of Medicine·interventional·Posted Oct 6, 2023·Updated Dec 18, 2025

In Brief

A Phase 2 clinical trial evaluating Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, and 2 other interventions for Onchocercal Subcutaneous Nodule and 4 related conditions. Active but no longer recruiting, targeting 300 participants across 1 site.

Detailed Summary

This study will investigate the safety and effectiveness of combination regimens in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and eyes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca Infection, Tropical Disease
CountriesLiberia
CollaboratorsNational Public Health Institute of Liberia

Timeline

Phase 2Active
202420252026
First PostedOct 6, 2023
Enrollment StartApr 5, 2024
Primary CompletionSep 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 2.7 years agoPrimary completion in 2 months

Interventions

Ivermectin w/ Albendazoledrug

Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)

Ivermectin + Diethylcarbamazine + Albendazoledrug

Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)

Moxidectin + Albendazoledrug

Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)

Moxidectin + Diethylcarbamazine + Albendazoledrug

Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)